Apr
01
2024
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
Mar
21
2024
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar
06
2024
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
Feb
26
2024
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
Feb
20
2024
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Feb
09
2024
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
Feb
07
2024
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
Jan
03
2024
Displaying 11 - 18 of 18